Skip to content

TRILURON

by Fidia Farmaceutici S.p.A.

PMA P180040

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P180040↗

FDA record

Trust

Unverified

Source FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP180040 Date26 Mar 2019ApprovedStatusActive

Official records

From the FDA record

FDA PMA P180040

Received by the FDA
27 Sep 2018
FDA decision
26 Mar 2019
FDA review time
180 days from receipt to decision
Docket number
19M-1465
Approval order statement, verbatim
Approval for TRILURON. The device is indicated for use in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

From the FDA PMA record P180040 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Full name
TRILURON® (sodium hyaluronate)
Trade name
Triluron
Generic name
Acid, hyaluronic, intraarticular
PMA number
FDA product code
MOZ
Device class
Class III
Advisory committee
Orthopedic
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

TRILURON is an intraarticular hyaluronic acid injection indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics such as acetaminophen. It is a sterile, single-use product supplied in pre-filled syringes for injection into the knee joint.

TRILURON is manufactured by Fidia Farmaceutici S.p.A. and is supplied as a sterile, single-use device. It is intended for use in clinical settings by qualified healthcare professionals. The device has received FDA PMA approval (P180040) and is classified as a Class III medical device under the generic name Acid, hyaluronic, intraarticular.

Devices cleared under P180040

3 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P180040
UDI-DISize and differences
TRILURON 89122-0879-01
Fidia Farmaceutici
89122-0879-01 / 89122-0879-01M713891220879010 —On the market
TriLURON M71389122087901A13
Fidia Farmaceutici
89122-0879-01 / M71389122087901A13M71389122087901A1 —No longer on the market
TriLURON M71389122087901SAM1A
Fidia Farmaceutici
FID10000317 / M71389122087901SAM1AM71389122087901SAM1 —No longer on the market

Similar devices

Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).

Other devices from Fidia Farmaceutici S.p.A.

See all devices from Fidia Farmaceutici S.p.A. →